Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25470927 | 0.83 | FAAH (0.47) | CYP2C19CYP1A2CYP2C9ALDH1A1POLB | |
| SCHEMBL15134826 | 0.81 | CYP1A2 (0.69) | CYP2C19CYP1A2CYP2C9ALDH1A1POLB | |
| SCHEMBL8235480 | 0.80 | ALDH1A1 (0.79) | CYP2C19CYP1A2CYP2C9ALDH1A1POLB | |
| SCHEMBL17460161 | 0.80 | PKM (0.57) | CYP2C19CYP1A2CYP2C9POLBKMT2A | |
| SCHEMBL12994617 | 0.79 | ALDH1A1 (0.82) | CYP2C19CYP1A2CYP2C9ALDH1A1POLB | |
| SCHEMBL8747161 | 0.78 | ALDH1A1 (0.79) | CYP2C19CYP1A2CYP2C9ALDH1A1POLB | |
| SCHEMBL10246301 | 0.77 | CYP1A2 (0.63) | CYP2C19CYP1A2CYP2C9ALDH1A1POLB | |
| SCHEMBL13043643 | 0.77 | CYP2C19 (0.63) | CYP2C19CYP1A2CYP2C9ALDH1A1POLB | |
| SCHEMBL8247308 | 0.76 | CYP1A2 (1.00) | CYP2C19CYP1A2CYP2C9POLBKMT2A | |
| SCHEMBL653157 | 0.76 | CYP1A2 (0.67) | CYP2C19CYP1A2CYP2C9ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230147603-A1 | HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | PROSETTA BIOSCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230147603-A1 | HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | PROSETTA BIOSCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023069770-A1 | NOVEL HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | PROSETTA BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | CYP2C19 3929/4885CYP1A2 4429/4885CYP2C9 4584/4885 |
| US-20230147603-A1 | HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | MAVS, SARS1, ZC3HAV1 | CYP2C19 3929/4885CYP1A2 4429/4885CYP2C9 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.